Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM). JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 11,000 | |||
5 mg | 在庫あり | ¥ 34,000 | |||
10 mg | 在庫あり | ¥ 50,000 | |||
25 mg | 在庫あり | ¥ 85,000 | |||
50 mg | 在庫あり | ¥ 125,000 | |||
100 mg | 在庫あり | ¥ 178,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 40,500 |
説明 | JNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM). JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. |
ターゲット&IC50 | PDGFRβ:4.2 nM, PDGFRα:45 nM |
In vitro | JNJ-10198409 has effective antiproliferative activity in six of eight human tumor cell lines (IC50<0.033 μM). It also is a potent inhibitor of the c-Abl kinase (IC50: 22 nM) [1,2]. |
別名 | JNJ-10198409 |
分子量 | 325.34 |
分子式 | C18H16FN3O2 |
CAS No. | 627518-40-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.33 mg/mL (256.13 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JNJ-10198409 627518-40-5 Angiogenesis Tyrosine Kinase/Adaptors PDGFR Platelet-derived growth factor receptor JNJ 10198409 inhibit JNJ-10198409 Inhibitor JNJ10198409 inhibitor